

## Pharmacy Policy

# Padcev

**Policy Number:** 9.707

**Version Number:** 2.0

**Version Effective Date:** 9/1/2021

### Product Applicability All Plan+ Products

#### Well Sense Health Plan

New Hampshire Medicaid

#### Boston Medical Center HealthNet Plan

MassHealth - MCO

MassHealth - ACO

Qualified Health Plans/ConnectorCare/Employer Choice Direct

Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

## Prior Authorization Policy

### Products Affected:

- Padcev (enfortumab vedotin-ejfv)

The Plan may authorize coverage of the above products for members meeting the following criteria:

<b>Covered Use</b>	All FDA approved indications not otherwise excluded
<b>Required Medical Information</b>	<ol style="list-style-type: none"> <li>1. Diagnosis of Urothelial carcinoma that is locally advanced or metastatic; <b>AND</b></li> <li>2. Member has previously received a programmed death receptor-1 ( PD-1) or programmed death-ligand 1 inhibitor (PD-L1inhibitor) (see Appendix A); <b>AND</b></li> <li>3. Member has previously received a platinum-containing chemotherapy; <b>AND</b></li> <li>4. Quantity being prescribed is consistent with dosing listed in manufacture package labeling</li> </ol>
<b>Age Restriction</b>	18 years and older
<b>Prescriber</b>	Prescribed by or in consultation with an oncologist

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

<b>Restriction</b>	
<b>Coverage Duration</b>	Initial: 6 months Reauthorization: 12 months
<b>Other criteria</b>	Reauthorization: 1. Clinical condition has improved or stabilized (decreased progression) without unacceptable treatment-related adverse events

Appendix A:

PD 1 Inhibitor	PD-L1 inhibitor
Keytruda	Tecentriq
Opdivo	Bavencio
Libtayo	Imfinzi

### Clinical Background Information and References

1. Padcev (enfortumab vedotin-ejfv) [prescribing information]. Bothell, WA: Seattle Genetics, Inc.; December 2019.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
12/1/2020	1/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History			
Review Date	Summary of Revisions	Revision Effective Date	Approved by
12/1/2020	9.205 Padcev Policy retired, new policy created	1/1/2021	P&T Committee
5/13/2021	P&T annual review. Removed documentation requirement; small update to reauthorization language.	9/1/2021	P&T Committee

### Next Review Date

5/2022

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

## Other Applicable Policies

---

## Reference to Applicable Laws and Regulations, If Any

---

### Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

\* *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.